ECSP13012596A - Proceso de elaboración para derivados de pirimidina - Google Patents

Proceso de elaboración para derivados de pirimidina

Info

Publication number
ECSP13012596A
ECSP13012596A ECSP13012596A ECSP13012596A EC SP13012596 A ECSP13012596 A EC SP13012596A EC SP13012596 A ECSP13012596 A EC SP13012596A EC SP13012596 A ECSP13012596 A EC SP13012596A
Authority
EC
Ecuador
Prior art keywords
solid forms
elaboration process
compound
pirimidine derivatives
pirimidine
Prior art date
Application number
Other languages
English (en)
Spanish (es)
Inventor
Piotr Karpinski
Prasad Koteswara Kapa
Baoqing Gong
Dietmar Flubacher
John Vincent Calienni
Liladhar Murlidhar Waykole
La Cruz Marilyn De
Hui Liu
Pascal Michel
Rasmus Mose
Maria Caterina Testa
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44773179&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP13012596(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ECSP13012596A publication Critical patent/ECSP13012596A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02Boron compounds
    • C07F5/025Boronic and borinic acid compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02Boron compounds
    • C07F5/04Esters of boric acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Pyridine Compounds (AREA)
ECSP13012596 2010-10-01 2013-04-30 Proceso de elaboración para derivados de pirimidina ECSP13012596A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38872110P 2010-10-01 2010-10-01
US201161494915P 2011-06-09 2011-06-09

Publications (1)

Publication Number Publication Date
ECSP13012596A true ECSP13012596A (es) 2013-07-31

Family

ID=44773179

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSP13012596 ECSP13012596A (es) 2010-10-01 2013-04-30 Proceso de elaboración para derivados de pirimidina

Country Status (31)

Country Link
US (3) US9181215B2 (fr)
EP (2) EP3040333B1 (fr)
JP (3) JP5998145B2 (fr)
KR (2) KR20180123586A (fr)
CN (3) CN104945373A (fr)
AR (1) AR083213A1 (fr)
AU (4) AU2011308856B2 (fr)
BR (1) BR112013007123B1 (fr)
CA (1) CA2813333C (fr)
CL (2) CL2013000850A1 (fr)
CO (1) CO6700837A2 (fr)
DK (1) DK3040333T3 (fr)
EC (1) ECSP13012596A (fr)
ES (1) ES2699951T3 (fr)
GT (1) GT201300080A (fr)
HK (1) HK1220686A1 (fr)
HU (1) HUE041326T2 (fr)
IL (3) IL225113A (fr)
LT (1) LT3040333T (fr)
MX (1) MX354482B (fr)
MY (1) MY160785A (fr)
NZ (1) NZ608285A (fr)
PE (1) PE20140002A1 (fr)
PH (1) PH12015501585A1 (fr)
PL (1) PL3040333T3 (fr)
PT (1) PT3040333T (fr)
RU (2) RU2576619C2 (fr)
SG (1) SG188439A1 (fr)
SI (1) SI3040333T1 (fr)
TW (1) TWI540133B (fr)
WO (1) WO2012044727A2 (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5832647B2 (ja) 2011-07-01 2015-12-16 ノバルティス アーゲー がんの治療における使用のためのcdk4/6阻害剤およびpi3k阻害剤を含む併用療法
WO2013046136A1 (fr) 2011-09-27 2013-04-04 Novartis Ag 3-pyrimidin-4-yl-oxazolidin-2-ones comme inhibiteurs d'idh mutante
UY34632A (es) 2012-02-24 2013-05-31 Novartis Ag Compuestos de oxazolidin- 2- ona y usos de los mismos
AU2013336807B2 (en) * 2012-10-23 2016-10-27 Novartis Ag Improved process for manufacturing 5-(2,6-Di-4-morpholinyl-4-pyrimidinyl)-4-trifluoromethylpyridin-2-amine
US9296733B2 (en) 2012-11-12 2016-03-29 Novartis Ag Oxazolidin-2-one-pyrimidine derivative and use thereof for the treatment of conditions, diseases and disorders dependent upon PI3 kinases
AP2015008707A0 (en) 2013-03-14 2015-09-30 Novartis Ag 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh
US9318944B2 (en) 2013-04-29 2016-04-19 Rockwell Automation Technologies, Inc. Methods and apparatus for active front end filter capacitor degradation detection
US9294005B2 (en) 2013-10-01 2016-03-22 Rockwell Automation Technologies, Inc. Method and apparatus for detecting AFE filter capacitor degradation
NZ718487A (en) * 2013-10-16 2020-01-31 Shanghai Yingli Pharm Co Ltd Fused heterocyclic compound, preparation method therefor, pharmaceutical composition, and uses thereof
BR112016023811B8 (pt) 2014-04-22 2023-01-10 Piqur Therapeutics Ag Método para fabricação para derivados de triazina, pirimidina e piridina, seus intermediários e seus métodos de fabricação
CN105085476B (zh) * 2014-11-24 2018-03-09 苏州晶云药物科技有限公司 5‑[2,6‑二(4‑吗啉基)‑4‑嘧啶基]‑4‑(三氟甲基)‑2‑吡啶胺二盐酸盐的晶型及其制备方法
US10227324B2 (en) 2014-12-17 2019-03-12 Shanghai Haiyan Pharmaceutical Technology Co., Ltd. 2-morpholin-4,6-disubstituted pyrimidine derivative, and preparation method and pharmaceutical use thereof
US9481665B2 (en) * 2015-03-13 2016-11-01 Yong Xu Process for preparing PI3K inhibitor buparsilib
CN107787226A (zh) 2015-03-25 2018-03-09 诺华股份有限公司 药物组合
CN105001151B (zh) * 2015-08-28 2017-07-14 苏州明锐医药科技有限公司 布帕尼西中间体及其制备方法
CN106543140A (zh) * 2015-09-21 2017-03-29 苏州晶云药物科技有限公司 5-[2,6-二(4-吗啉基)-4-嘧啶基]-4-(三氟甲基)-2-吡啶胺盐酸盐的晶型及其制备方法
ES2907574T3 (es) * 2015-12-16 2022-04-25 Genentech Inc Proceso para la preparación de compuestos inhibidores de pi3k triciclicos y métodos para su utilización para el tratamiento del cáncer.
CN106905294A (zh) * 2016-07-08 2017-06-30 苏州科睿思制药有限公司 5‑[2,6‑二(4‑吗啉基)‑4‑嘧啶基]‑4‑(三氟甲基)‑2‑吡啶胺的晶型及其制备方法
CN107793394A (zh) * 2017-08-03 2018-03-13 上海厚璞生物科技有限公司 一种生产选择性pi3k抑制剂的系列关键中间体
CN110016142B (zh) * 2019-04-30 2021-08-03 合肥工业大学 一种含嘧啶硼酸结构的硅油及其制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6124476A (en) 1998-04-17 2000-09-26 Symyx Technologies, Inc. Catalyst ligands, catalyst compositions, catalyst metal complexes and processes for cross-coupling aromatic boron compounds with aromatic halogens or perfluoroalkylsulfonates
CN1735598A (zh) * 2002-11-11 2006-02-15 拜耳医药保健股份公司 作为ip受体拮抗剂的苯基或杂芳基氨基烷烃衍生物
EA013811B1 (ru) 2002-11-21 2010-08-30 Новартис Вэксинес Энд Дайэгностикс, Инк. 2,4,6-тризамещённые пиримидины, являющиеся ингибиторами фосфотидилинозитол(pi)-3-киназы, и их применение при лечении рака
JO2660B1 (en) * 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
EP2057140B1 (fr) 2006-08-24 2012-08-08 AstraZeneca AB Dérivés de la morpholino pyrimidine utiles dans le traitement de maladies prolifératives
CN101711241A (zh) * 2007-02-06 2010-05-19 诺瓦提斯公司 Pi3-激酶抑制剂和它们的使用方法
WO2009066084A1 (fr) * 2007-11-21 2009-05-28 F. Hoffmann-La Roche Ag 2-morpholinopyrimidines et leur utilisation en tant qu'inhibiteurs de kinase pi3
AU2010247397B2 (en) * 2009-05-15 2012-07-12 Novartis Ag Combination of a phosphoinositide 3-kinase inhibitor and an antidiabetic compound

Also Published As

Publication number Publication date
AU2011308856B2 (en) 2015-04-23
NZ608285A (en) 2014-06-27
US20150232446A1 (en) 2015-08-20
RU2013120326A (ru) 2014-11-20
AR083213A1 (es) 2013-02-06
CL2015001088A1 (es) 2015-07-10
CN104945373A (zh) 2015-09-30
RU2576619C2 (ru) 2016-03-10
CL2013000850A1 (es) 2013-09-27
SG188439A1 (en) 2013-05-31
JP2016106091A (ja) 2016-06-16
CA2813333A1 (fr) 2012-04-05
IL233282A0 (en) 2014-08-31
AU2015200938B2 (en) 2015-11-19
JP5998145B2 (ja) 2016-09-28
HK1220686A1 (zh) 2017-05-12
DK3040333T3 (da) 2019-01-02
US20130225571A1 (en) 2013-08-29
ES2699951T3 (es) 2019-02-13
SI3040333T1 (sl) 2019-01-31
CN103140479A (zh) 2013-06-05
CN103140479B (zh) 2015-04-08
EP3040333A1 (fr) 2016-07-06
AU2015200938A1 (en) 2015-03-12
MX354482B (es) 2018-03-07
PE20140002A1 (es) 2014-01-21
LT3040333T (lt) 2018-12-10
BR112013007123A2 (pt) 2016-06-14
JP2013541536A (ja) 2013-11-14
MY160785A (en) 2017-03-15
AU2015200936A1 (en) 2015-03-12
RU2015150728A (ru) 2019-01-15
US9359326B2 (en) 2016-06-07
IL238046A (en) 2016-08-31
CN104987321A (zh) 2015-10-21
AU2011308856A1 (en) 2013-03-28
AU2015246141A1 (en) 2015-11-12
BR112013007123B1 (pt) 2021-11-09
JP2016128414A (ja) 2016-07-14
US20160251334A1 (en) 2016-09-01
EP3040333B1 (fr) 2018-09-12
GT201300080A (es) 2014-07-18
WO2012044727A2 (fr) 2012-04-05
TW201215605A (en) 2012-04-16
KR20130119928A (ko) 2013-11-01
HUE041326T2 (hu) 2019-05-28
US9452994B2 (en) 2016-09-27
PT3040333T (pt) 2018-12-04
PH12015501585A1 (en) 2015-09-21
WO2012044727A3 (fr) 2012-06-07
IL225113A (en) 2016-08-31
AU2015246141B2 (en) 2016-07-07
US9181215B2 (en) 2015-11-10
TWI540133B (zh) 2016-07-01
CA2813333C (fr) 2019-01-15
MX2013003507A (es) 2013-05-20
IL233282A (en) 2016-08-31
PL3040333T3 (pl) 2019-03-29
EP2621908A2 (fr) 2013-08-07
KR20180123586A (ko) 2018-11-16
CO6700837A2 (es) 2013-06-28

Similar Documents

Publication Publication Date Title
ECSP13012596A (es) Proceso de elaboración para derivados de pirimidina
UY32096A (es) Derivados de 2-carboxamida - cicloamino - urea especìficos, sus sales farmacèuticamente aceptables, composiciones contenièndolos, pro-farmacos de los mismos, procesos para su produciòn y aplicaciones
CU24605B1 (es) Pirimidin-2-il amino-1h-pirazoles útiles como inhibidores de lrrk2
CR20150472A (es) USO DE DERIVADOS DE PIRAZOLOPIRIMIDINA PARA EL TRATAMIENTO DE TRANSTORNOS RELACIONADOS CON LA PI3Kd
NI201500123A (es) Inhibidores quinazolínicos de formas mutadas activantes del receptor del factor de crecimiento epidérmico
CR20140548A (es) Derivados de aril-sultamo como moduladores de rorc
CR20140413A (es) Inhibidores de serina/treonina cinasa
CO6781507A2 (es) Novedosos derivados heterociclicos
CR20140399A (es) Pirrolidina-2-carboxamidas sustituidas
CU20120099A7 (es) Derivados de pirazina y su uso en el tratamiento de trastornos neurológicos
CU20160192A7 (es) Derivados de indano e indolina útiles como activadores de la guanilato ciclasa soluble
PE20180318A1 (es) Procedimiento para preparar isoquinolinonas y formas solidas de isoquinolinonas
ECSP15012804A (es) Alcoxipirazoles como activadores de guanilato ciclasa soluble
DOP2014000036A (es) Compuestos de piridazinona y su uso como inhibidores daao
ECSP11011206A (es) Nuevos herbicidas.
ECSP11011244A (es) Nuevos herbicidas.
CR20150378A (es) Compuestos tetracíclicos sustituidos con heterociclo y métodos de uso de los mismos para el tratamiento de enfermedades víricas
DOP2015000076A (es) Benzamidas
ECSP099722A (es) Compuestos de pirido [2, 3-d] pirimidina-7-ona como inhibidores de pi3k-alfa para el tratamiento del cáncer
CR20150245A (es) Proceso novedoso para la elaboración de compuestos para uso en el tratamiento de cáncer
CU20110220A7 (es) Espiro-epóxidos como productos intermedios
CR20160016A (es) Pirazolpiridinas sustituidas
CR20140325A (es) Nuevos derivados de morofolinilo útiles como inhibodores de mogat-2-
UY36228A (es) Derivados de heteroarilo como inhibidores de aldosterona sintasa (cyp11b2) y composiciones farmacéuticas que los contienen
ECSP13012548A (es) Inhibidores de oxadiazol de la producción de leucotrienos.